Doylestown Plus与GALAD在肝硬化患者中检测肝细胞癌的敏感性
本研究在肝硬化患者巢式病例对照研究中比较包括AFP、GALAD和Doylestown Plus在内的多种生物标志物对肝细胞癌(HCC)的检测性能。背景指出半年一次腹部超声联合或不联合AFP的监测策略在早期阶段遗漏超过三分之一的HCC,而GALAD和Doylestown Plus在II期病例对照研究中显示有前景的准确性,但病例对照研究可能高估性能,需III期队列研究验证。
要点
- 半年一次超声联合或不联合AFP监测在早期阶段遗漏超过三分之一的HCC。
- GALAD和Doylestown Plus在II期病例对照研究中显示有前景的准确性。
- 病例对照研究可能高估生物标志物性能,需III期研究验证。
核心结论
- 研究旨在肝硬化患者巢式病例对照研究中比较AFP、GALAD和Doylestown Plus等多种生物标志物对HCC的检测性能。
研究设计与样本
- 巢式病例对照研究,对象为肝硬化患者。
主要发现
- 半年一次腹部超声联合或不联合AFP监测在早期阶段遗漏超过三分之一的HCC。
- GALAD和Doylestown Plus在II期病例对照研究中显示有前景的准确性。
局限性
- 病例对照研究可能高估生物标志物性能,需III期队列和巢式病例对照研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hepatocellular carcinoma (HCC) surveillance is associated with early tumor detection and improved survival in patients with cirrhosis.1 Surveillance is performed using semiannual abdominal ultrasound with or without α-fetoprotein (AFP); however, this strategy misses more than one-third of HCC at an early stage.2 These data highlight a need for novel surveillance strategies with higher accuracy for early HCC detection. GALAD and Doylestown Plus are novel biomarker panels that combine multiple biomarkers with patient demographic and clinical characteristics; both demonstrated promising accuracy in phase II case-control studies;3,4 however, case-control studies can overestimate biomarker performance, highlighting a need for phase III cohort and nested case-control studies.5 Our study aimed to compare multiple biomarkers (including AFP, GALAD, and Doylestown Plus) in a nested case-control study of patients with cirrhosis.
引用
- Singal AG, Tayob N, Mehta A, et al. Doylestown Plus and GALAD Demonstrate High Sensitivity for HCC Detection in Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2021. PMID: 33864933. doi:10.1016/j.cgh.2021.04.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。